ArticleEBioMedicine2026
irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Validation of International Classification of Diseases Code-Based Case Definitions of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis From Administrative Health Data.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Hierarchical prompting with reasoning large language models for immune checkpoint inhibitor-associated myocarditis evidence extraction pilot study.European heart journal. Digital health · 2026Article
- Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity.medRxiv : the preprint server for health sciences · 2026Article
- The Performance of Large Language Models in Extracting Intestinal Symptoms From Electronic Health Records: Retrospective Observational Study.Journal of medical Internet research · 2026Observational
- Extracting adverse event nature, severity, timelines and resulting interventions from clinical notes of patients receiving CAR-T cell therapy using large language models.PLOS digital health · 2026Article
- Article
- Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Extracting adverse event nature, severity, timelines and resulting interventions from clinical notes of patients receiving CAR-T therapy using large language models.medRxiv : the preprint server for health sciences · 2026Article
- An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation study.medRxiv : the preprint server for health sciences · 2026Article
- Artificial intelligence for optimization of immunotherapy: current applications and transformative potential.Frontiers in immunology · 2026Review
- Large Language Models for Drug-Related Adverse Events in Oncology Pharmacy: Detection, Grading, and Actioning.Pharmacy (Basel, Switzerland) · 2025Review
- Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial.Journal of the American Heart Association · 2025Article
- Large Language Models for Adverse Drug Events: A Clinical Perspective.Journal of clinical medicine · 2025Review
- Exploring perceptions of data risks in AI-enabled nursing research: A qualitative study.Digital healthArticle
Corrections and comments
- Update of
Authors and funding
20 authors.
Funding
Abstract
backgroundLarge language models (LLMs) have emerged as transformative technologies, revolutionising natural language understanding and generation across various domains, including medicine. In this study, we investigated the capabilities, limitations, and generalisability of Generative Pre-trained Transformer (GPT) models in analysing unstructured patient notes from large healthcare datasets to identify immune-related adverse events (irAEs) associated with the use of immune checkpoint inhibitor (ICI) therapy.
methodsWe evaluated the performance of GPT-3.5, GPT-4, and GPT-4o models on manually annotated datasets of patients receiving ICI therapy, sampled from two electronic health record (EHR) systems and seven clinical trials. A zero-shot prompt was designed to exhaustively identify irAEs at both the patient level (main analysis) and the note level (secondary analysis). The LLM-based system followed a multi-label classification approach to identify any combination of irAEs associated with individual patients or clinical notes. System evaluation was conducted for each available irAE as well as for broader categories of irAEs classified at the organ level.
findingsOur analysis included 442 patients across three institutions. The most common irAEs manually identified in the patient datasets included pneumonitis (N = 64), colitis (N = 56), rash (N = 32), and hepatitis (N = 28). The GPT models demonstrated generalisable abilities in identifying irAEs across EHRs and clinical trial reports. Overall, the models achieved relatively high sensitivity and specificity but only moderate positive predictive values, reflecting a potential bias towards overpredicting irAE outcomes. GPT-4o achieved the highest F1 and micro-averaged F1 scores for both patient-level and note-level evaluations. Highest performance was observed in the haematological (F1 range = 1.0-1.0), gastrointestinal (F1 range = 0.81-0.85), and musculoskeletal and rheumatologic (F1 range = 0.67-1.0) irAE categories. Error analysis uncovered substantial limitations of GPT models in handling textual causation, where adverse events should not only be accurately identified in clinical text but also causally linked to immune checkpoint inhibitors.
interpretationThis study demonstrated that GPT models can automate the detection of immune related adverse events in varied healthcare datasets, reducing the burden on physicians and other healthcare professionals by limiting the need for manual review. This capability will accelerate the generation of safety insights across large healthcare datasets and facilitate the characterisation of patient-level drivers of toxicities, thus enhancing safety monitoring and ultimately improving patient care.
fundingNational Institutes of Health, Roche, National Health and Medical Research Council of Australia, Stevens-Johnson Syndrome Foundation, Angela Anderson Research Fund, Larry L Hillblom Foundation and UCSF Research Allocation Program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.